Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Dermatol Ther ; 32(4): e12937, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-30983098

RESUMO

A descriptive retrospective, study comparing the first 29 patients who received ustekinumab at our unit following its approval in September 2009 with 30 patients who received secukinumab after its marketing in Spain in November 2015 was conducted. The secukinumab treatment group showed higher whitening rates and a higher percentage of patients reached a psoriasis area and severity index (PASI) 75 response (89.65 vs. 73.33%, p = .108) than those in the ustekinumab treatment group at Week 52. The number of patients achieving a PASI 90 response was particularly remarkable and statistically significant (82.75 vs. 43.33%, p = .002). Better PASI 75 response rates were also observed in the secukinumab group than in the ustekinumab group after 52 weeks in biologic-naïve patients (89 vs. 72%, p = .586) and among those previously treated with one line (92 vs. 100%, p = 1.00) or with two or more previous biologic lines (88 vs. 62%, p = .336). These differences were greater in the number of patients reaching a PASI 90 response in the secukinumab group than in the ustekinumab group in biologic-naïve patients (78 vs. 63%, p = .642) and in those previously treated with one (92 vs. 50%, p = .083) or with two or more treatment lines (75 vs. 31%, p = .080). These regular-practice results overlap or surpass those obtained in the CLEAR clinical trial.


Assuntos
Anticorpos Monoclonais Humanizados/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Psoríase/tratamento farmacológico , Ustekinumab/administração & dosagem , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Psoríase/patologia , Estudos Retrospectivos , Índice de Gravidade de Doença , Espanha , Resultado do Tratamento
2.
Front Med (Lausanne) ; 10: 1260514, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37928475

RESUMO

Background: Summer and spring eruptions on the elbows are a variant of polymorphous light eruption described on clinical and histopathological grounds; however, to our knowledge, they have not been confirmed by photobiological studies. Objective: Based on photobiological studies, this study aimed to demonstrate the involvement of ultraviolet-A (UVA) radiation in this variant of polymorphous light eruption occurring exclusively on the elbows. Methods: A series of five patients with polymorphous light eruption lesions on the elbows were included in our study. All patients underwent phototesting and photoprovocation of the skin lesions after exposure to a UVA light source [Philips UVA HPA lamp (400 W)]. All patients underwent punch biopsy and histopathological and immunohistochemical studies with anti-CD123. Results: In all the cases, UVA irradiation caused the appearance of skin lesions on the elbows with characteristic polymorphous light eruption. Histological data showed edema in the superficial dermis and a perivascular lymphocytic infiltrate compatible with polymorphous light eruption. Immunohistochemical staining for CD1-23 showed negative results. Conclusions: For the first time, photobiological photoprovocation studies demonstrated that repeated exposure to UVA radiation leads to the generation of skin lesions on the elbows, which are clinically and histologically consistent with summer and spring eruptions, confirming that elbow rash is a variant of polymorphous light eruption.

3.
Am J Dermatopathol ; 30(3): 262-4, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18496428

RESUMO

Composite cutaneous hemangioendothelioma (HE) is the most recently described variant of the lesions known as HEs. It is characterized by a mixture of histologic patterns, namely, epithelioid HE, retiform HE, and spindle cell hemangioma. We report a new case of this rare tumor located on the back of a 23-year-old woman. This neoplasm is considered to be of borderline or low-grade malignancy, because despite its frequency it rarely metastasizes.


Assuntos
Hemangioendotelioma Epitelioide/patologia , Neoplasias Cutâneas/patologia , Adulto , Dorso , Biomarcadores Tumorais/análise , Células Epitelioides/química , Células Epitelioides/patologia , Feminino , Hemangioendotelioma Epitelioide/química , Hemangioendotelioma Epitelioide/cirurgia , Humanos , Recidiva Local de Neoplasia/patologia , Recidiva Local de Neoplasia/cirurgia , Molécula-1 de Adesão Celular Endotelial a Plaquetas/análise , Neoplasias Cutâneas/química , Neoplasias Cutâneas/cirurgia , Resultado do Tratamento
4.
Am J Dermatopathol ; 24(2): 139-43, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11979074

RESUMO

A 58-year-old woman presented with a pilomatrix carcinoma on the right knee. The tumor developed at the site of a previous lesion that had been present since she was 30 years old. Histologic study showed the presence of basaloid cells with numerous atypical mitoses, shadow cells, and calcification. After several surgical excisions, the tumor mass infiltrated the subcutaneous tissue, muscle, and bone, resulting in inguinal lymph node and pulmonary metastasis. We also review the literature and comment on the histopathologic differences from other cutaneous tumors.


Assuntos
Doenças do Cabelo/patologia , Neoplasias Pulmonares/secundário , Linfonodos/patologia , Pilomatrixoma/secundário , Neoplasias Cutâneas/patologia , Calcinose/patologia , Feminino , Doenças do Cabelo/cirurgia , Humanos , Joelho/patologia , Metástase Linfática , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Pilomatrixoma/cirurgia , Neoplasias Cutâneas/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA